The selective estrogen receptor modulators in breast cancer prevention

  title={The selective estrogen receptor modulators in breast cancer prevention},
  author={Fangxuan Li and Jinli Dou and Li-juan Wei and Shi-xia Li and Juntian Liu},
  journal={Cancer Chemotherapy and Pharmacology},
AbstractBackgrounds Persistently increased blood levels of estrogens are associated with an increased risk of breast cancer. Selective estrogen receptor modulators (SERMs) are a class of compounds that act on the estrogen receptor (ER).Methods Several clinical trials have demonstrated the effectiveness of its prophylactic administration. Incidence of invasive ER-positive breast cancer was reduced by SERMs treatment, especially for those women with high risk of developing breast cancer. In this… 

Menopausal Hormonal Therapy and Breast Cancer

It was found that hormone-dependent forms of cancer developed more often in women using MHT, but by the time of diagnosis, the disease was found in more advanced stages and metastases in lymph nodes were found more often when compared with patients who did not use MHT.

Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer

Understanding the mechanisms of the effects of estrogen and androgen on breast cancer and prostate cancer may help to improve curative BC and PC treatment strategies.

The effect and safety of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in women: a protocol for systematic review and meta-analysis

A systematic review and meta-analysis addressing the effect and safety of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in women and the risks of known adverse outcomes in the already vulnerable chronic kidney disease population is evaluated.

A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer

AR:ERα and PDEF:ER α ratios are independent predictors of the response to conventional ERα-directed tamoxifen endocrine therapy and were independent predictor of DFS and DSS.

ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer

An overview of ZNF423 expression and functional role in human malignancies, with a specific focus on its implication in hormone-responsive BC is provided.

BRCA1/P53: Two strengths in cancer chemoprevention.

Neuropsychiatric effects of tamoxifen: Challenges and opportunities

Impact of Stilbenes as Epigenetic Modulators of Breast Cancer Risk and Associated Biomarkers

This review will explore means of exploiting the abilities of stilbenes in altering the underlying factors that influence breast cancer risk, as well as the appearance of associated biomarkers.

Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.

The results suggest reasonable uptake of risk-reducing interventions in high-risk women and more attention could be paid to ensuring that affected women receive proper counselling and follow-up.



Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

A 0.5-mg dose of lasofoxifene appears to reduce the risks of both total and ER+ invasive breast cancer in postmenopausal women with osteoporosis.

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

Use of tamoxifen and raloxifene for prevention of primary breast cancers continues to be low, and in 2010, women reporting medication use for breast cancer chemoprevention were primarily using the more recently FDA approved drug ral oxifene.

The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.

  • T. Bevers
  • Medicine
    Journal of the National Comprehensive Cancer Network : JNCCN
  • 2007
Since the unblinding of the STAR trial in 2006, raloxifene has emerged as an option for reducing breast cancer risk for postmenopausal women at increased risk for the disease.

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

Several blood biomarkers showed dose-response relationships with tamoxifen, including decreased insulin-like growth factor-I, increased sex hormone-binding globulin, and decreased low-density lipoprotein-cholesterol, ultrasensitive C-reactive protein, fibrinogen, and antithrombin-III levels.

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

Clinical trial data on selective estrogen receptor modulators and aromatase inhibitors have demonstrated reduced breast cancer incidence in the prevention setting among high-risk women, but uptake of chemoprevention has been low due to barriers in identifying high- risk women, lack of understanding of risks and benefits, as well as concerns about side effects.

Overview of the main outcomes in breast-cancer prevention trials

Current strategies for the prevention of breast cancer

The objective of this review is to summarize the various approaches directed at reducing the incidence of breast cancer.

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.

Chemoprevention of breast cancer with tamoxifen appears to be effective in women at high risk of ER+ tumors but not among women at low risk, who may well be protected naturally by late age at menarche or early first pregnancy, or artificially by removal of the ovaries.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.